01—Abstract
Summary
Summary of the 10-Q filed April 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported net income of $123.9 milliona for the quarter ended March 31, 2026, up from $114.6 million in the prior-year quarter, with diluted EPS of $4.28 versus $3.67.
Revenue, net rose $148.0 millionb (26.5%) to $706.6 million, driven primarily by growth in the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, rose $109.6 million, and total direct costs increased to $510.3 million from $380.2 million. Selling, general and administrative expenses fell $10.0 million to $47.9 million, mainly due to lower stock-based compensation.
The balance sheet strengthened over the quarter. Cash and cash equivalents increased to $652.7 millionc from $497.0 million at December 31, 2025, and the company reported no indebtedness under its $10.0 million Credit Facility. Operating cash flow was $151.8 million, and shareholders' equity rose to $598.3 million from $459.1 million.
The company did not repurchase any shares in the quarter, leaving $821.7 milliond of remaining authorization, compared with $389.8 million of repurchases in the prior-year quarter. Net new business awards were $618.4 million, and backlog reached $2,929.2 million.
A securities class action was filed on April 6, 2026, in the U.S. District Court for the Southern District of Ohio against the company and three officers, alleging materially false and misleading statements about the book-to-bill ratio. The company has recorded no liability for the matter because a loss is not currently probable or reasonably estimable.
02—Key points
Key Highlights
- Revenue, net of $706.6 million, up $148.0 million (26.5%) from $558.6 million in the prior-year quarter.
- Net income of $123.9 million and diluted EPS of $4.28, compared with $114.6 million and $3.67 a year earlier.
- Income from operations of $141.5 million, up from $113.5 million; the effective tax rate rose to 16.1% from 3.0%.
- Cash and cash equivalents of $652.7 million at March 31, 2026, up from $497.0 million at year-end 2025, with no debt outstanding.
- Net new business awards of $618.4 million and backlog of $2,929.2 million, up 2.9% year over year.
- No share repurchases in the quarter, versus $389.8 million repurchased in the first quarter of 2025; $821.7 million of authorization remains.
- Securities class action filed April 6, 2026 alleging misleading statements about the book-to-bill ratio; no liability recognized.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed April 23, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $706.60M$558.57M | +26.5% |
| SG&A Expenses | $47.92M$57.90M | −17.2% |
| Operating Expenses | $565.10M$445.05M | +27.0% |
| Operating Income | $141.50M$113.52M | +24.6% |
| Net Income | $123.87M$114.59M | +8.1% |
| EPS (Basic) | $4.35$3.77 | +15.4% |
| EPS (Diluted) | $4.28$3.67 | +16.6% |
| Shares Outstanding (Basic) | 28.45M30.39M | −6.4% |
| Shares Outstanding (Diluted) | 28.96M31.20M | −7.2% |
05—Questions
Frequently Asked Questions
What drove the increase in revenue this quarter?
Total revenue increased $148.0 million to $706.6 million, primarily driven by growth in the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas compared with the same period a year earlier.
Why did total direct costs rise so sharply?
Total direct costs increased $130.1 million to $510.3 million, mainly due to a $109.6 million increase in reimbursed out-of-pocket expenses, which the filing notes can fluctuate significantly based on the timing of program initiation and closeout, and a $20.7 million increase in personnel costs.
How strong is the company's liquidity position?
Cash and cash equivalents rose to $652.7 million from $497.0 million at December 31, 2025. Operating cash flow was $151.8 million, and the company had no indebtedness, with its $10.0 million revolving Credit Facility fully available.
What is the status of the share repurchase program?
The company did not repurchase any shares in the first quarter of 2026. It had $821.7 million of remaining authorization under its share repurchase program as of March 31, 2026.
What legal matter should investors be aware of?
On April 6, 2026, a class action complaint was filed in the U.S. District Court for the Southern District of Ohio against Medpace Holdings, Inc. and three officers, alleging violations of federal securities laws related to statements about the book-to-bill ratio. The complaint seeks unspecified damages, and the company has not recognized a liability because a loss is not currently probable or reasonably estimable.
06—Continue